| Overview |
| bs-9930R-Cy7 |
| KCNE2 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human KCNE2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9992 |
| ATFB4; cardiac voltage gated potassium channel accessory subunit 2; Kcne2; KCNE2_HUMAN; LQT5; LQT6; minimum potassium ion channel related peptide 1; Minimum potassium ion channel-related peptide 1 antibody minK related peptide 1; MinK-related peptide 1; MIRP1; Potassium channel subunit beta MiRP1; potassium channel subunit, MiRP1; potassium voltage gated channel subfamily E member 2; potassium voltage gated channel, Isk related family, member 2; Potassium voltage-gated channel subfamily E member 2; voltage-gated K+ channel subunit MIRP1. |
| Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Associated with KCNH2/HERG is proposed to form the rapidly activating component of the delayed rectifying potassium current in heart (IKr). May associate with KCNQ2 and/or KCNQ3 and modulate the native M-type current. May associate with KCNQ1/KVLTQ1 and elicit a voltage-independent current. May associate with HCN1 and HCN2 and increase potassium current. |
| Application Dilution |
| WB |
1:300-5000 |
| IF |
IHC-P1:50-200 |
Powered by Bioz